RT Journal Article
SR Electronic
T1 Chikungunya Virus VLP Vaccine: Phase 3 Trial in Adolescents and Adults
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.10.11.24315179
DO 10.1101/2024.10.11.24315179
A1 Richardson, Jason S.
A1 Anderson, Deborah M.
A1 Mendy, Jason
A1 Tindale, Lauren C.
A1 Muhammad, Sufia
A1 Loreth, Tobi
A1 Tredo, Sarah Royalty
A1 Warfield, Kelly L.
A1 Ramanathan, Roshan
A1 Caso, Jorge T.
A1 Jenkins, Victoria A.
A1 Ajiboye, Patrick
A1 Bedell, Lisa
A1 ,
YR 2024
UL http://medrxiv.org/content/early/2024/10/15/2024.10.11.24315179.abstract
AB Background Chikungunya disease is a growing global public health concern. Chikungunya virus (CHIKV) virus-like particle (VLP) vaccine is a single dose, pre-filled syringe for intramuscular injection.Methods A pivotal phase 3 randomized, double-blind, placebo-controlled trial was conducted in healthy adolescents and adults 12-64 years of age. Participants received either CHIKV VLP vaccine or placebo on Day 1. Immunogenicity objectives assessed CHIKV serum neutralizing antibody (SNA) titers (NT80) at selected timepoints. Safety was assessed through Day 183 postvaccination.Results A total of 2790 participants received CHIKV VLP vaccine and 464 received placebo (n=3454). Coprimary endpoints were met including 1) immunologic superiority to placebo and 2) geometric mean titer at Day 22. Results demonstrated that CHIKV VLP vaccine induced a protective seroresponse (SNA NT80 ≥100; considered the presumptive seroprotective antibody response), in 97% of individuals at Day 15 (2 weeks), in 98% of individuals at Day 22, and in 86% of individuals at Day 183 (6 months). CHIKV VLP vaccine demonstrated a favorable safety profile. The majority of adverse events were self-limited and grade 1 or 2 in severity. The most common adverse events were injection site pain, fatigue, headache, and myalgia.Conclusions CHIKV VLP vaccine induces a rapid and robust immune response by Day 15 that lasts through Day 183 postvaccination. These findings support the potential for this vaccine to protect individuals 12-64 years of age from disease caused by CHIKV. (Funded by Emergent BioSolutions Inc. and Bavarian Nordic A/S [as successor in interest to Emergent BioSolutions Inc.]; ClinicalTrials.gov number, NCT05072080).Competing Interest StatementAll authors are current or previous employees/contractors of Bavarian Nordic and/or Emergent BioSolutions.Clinical TrialNCT05072080Clinical Protocols https://clinicaltrials.gov/study/NCT05072080 Funding StatementThis study was funded by Emergent BioSolutions Inc. and Bavarian Nordic A/S [as successor in interest to Emergent BioSolutions Inc.]Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:WCG (Western-Copernicus Group) Institutional Review Board gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesDe-identified data produced in the present study are available upon reasonable request to the authors.